Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn's disease

被引:2
|
作者
Li, Yong [1 ,2 ]
Sun, Ruizheng [3 ]
Lai, Chen [3 ]
Liu, Kezhen [4 ]
Yang, Huixiang [1 ,2 ]
Peng, Ziheng [1 ,2 ]
Xu, Duo [1 ,2 ]
Huang, Fangling [5 ]
Tang, Keke [1 ,2 ]
Peng, Yu [1 ,2 ,6 ]
Liu, Xiaowei [1 ,2 ,6 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China
[2] Xiangya Hosp, Hunan Key Lab Precise Diag & Treatment Gastrointe, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China
[4] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA
[5] Cent South Univ, Xiangya Hosp, Dept Hyperbar Oxygen, Changsha 410008, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorder, Changsha 410008, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Hyperbaric oxygen therapy; Crohn's disease; Gut microbiota; Inflammation; Fecal microbiota transplantation; MECHANISMS; ALPHA;
D O I
10.1186/s12967-024-05317-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Dysbiosis of the gut microbiota is pivotal in Crohn's disease (CD) and modulated by host physiological conditions. Hyperbaric oxygen therapy (HBOT) is a promising treatment for CD that can regulate gut microbiota. The relationship between HBOT and the gut microbiota in CD remains unknown.Methods CD patients were divided into an HBOT group (n = 10) and a control group (n = 10) in this open-label prospective interventional study. The fecal samples before and after HBOT were used for 16 S rRNA gene sequencing and fecal microbiota transplantation (FMT). A colitis mouse model was constructed using dextran sulfate sodium, and intestinal and systematic inflammation was evaluated. The safety and long-term effect of HBOT were observed.Results HBOT significantly reduced the level of C-reactive protein (CRP) (80.79 +/- 42.05 mg/L vs. 33.32 +/- 18.31 mg/L, P = 0.004) and the Crohn's Disease Activity Index (CDAI) (274.87 +/- 65.54 vs. 221.54 +/- 41.89, P = 0.044). HBOT elevated the declined microbial diversity and ameliorated the altered composition of gut microbiota in patients with CD. The relative abundance of Escherichia decreased, and that of Bifidobacterium and Clostridium XIVa increased after HBOT. Mice receiving FMT from donors after HBOT had significantly less intestinal inflammation and serum CRP than the group before HBOT. HBOT was safe and well-tolerated by patients with CD. Combined with ustekinumab, more patients treated with HBOT achieved clinical response (30%vs.70%, P = 0.089) and remission (20%vs.50%, P = 0.160) at week 4.Conclusions HBOT modulates the dysbiosis of gut microbiota in CD and ameliorates intestinal and systematic inflammation. HBOT is a safe option for CD and exhibits a promising auxiliary effect to ustekinumab.Trial registration Chinese Clinical Trial Registry, ChiCTR2200061193. Registered 15 June 2022, https://www.chictr.org.cn/showproj.html?proj=171605.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Dysbiosis of Gut Fungal Microbiota is Associated With Mucosal Inflammation in Crohn's Disease
    Li, Qiurong
    Wang, Chenyang
    Tang, Chun
    Ms, Qin He
    Li, Ning
    Li, Jieshou
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (06) : 513 - 523
  • [2] Crohn's disease and hyperbaric oxygen therapy
    Iezzi, Leonardo Estenio
    Feitosa, Marley Ribeiro
    Medeiros, Bruno Amaral
    Aquino, Jussara C.
    Normanha Ribeiro de Almeida, Ana Luiza
    Parra, Rogerio Serafim
    Ribeiro da Rocha, Jose Joaquim
    Feres, Omar
    ACTA CIRURGICA BRASILEIRA, 2011, 26 : 129 - 132
  • [3] Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot study
    Sangfuang, Nannapat
    Mccoubrey, Laura E.
    Awad, Atheer
    Marzorati, Massimo
    Ghyselinck, Jonas
    Verstrepen, Lynn
    De Munck, Julie
    De Medts, Jelle
    Gaisford, Simon
    Basit, Abdul W.
    TRANSLATIONAL RESEARCH, 2025, 278 : 36 - 47
  • [4] Hyperbaric oxygen therapy ameliorates osteonecrosis in patients by modulating inflammation and oxidative stress
    Bosco, Gerardo
    Vezzani, Giuliano
    Sposta, Simona Mrakic
    Rizzato, Alex
    Enten, Garrett
    Abou-samra, Abdullah
    Malacrida, Sandro
    Quartesan, Silvia
    Vezzoli, Alessandra
    Camporesi, Enrico
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2018, 33 (01) : 1501 - 1505
  • [5] Hyperbaric oxygen therapy for perineal Crohn's disease
    Noyer, CM
    Brandt, LJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (02): : 318 - 321
  • [6] Hyperbaric Oxygen Therapy in the Treatment of Crohn's Disease
    Krstulovic, Jure
    Augustin, Goran
    Romic, Ivan
    Tavra, Ante
    Batinovic, Franko
    Hrgovic, Zrinka
    HEALTHCARE, 2025, 13 (02)
  • [7] Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease
    Ribaldone, Davide Giuseppe
    Caviglia, Gian Paolo
    Abdulle, Amina
    Pellicano, Rinaldo
    Ditto, Maria Chiara
    Morino, Mario
    Fusaro, Enrico
    Saracco, Giorgio Maria
    Bugianesi, Elisabetta
    Astegiano, Marco
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [8] TARAXASTEROL AMELIORATES DSS-INDUCED COLITIS THROUGH IMPROVING INTESTINAL BARRIER AND MODULATING GUT MICROBIOTA DYSBIOSIS
    Chen, Wei
    Li, Chen
    Wang, Meng
    GUT, 2022, 71 : A46 - A47
  • [9] Contribution of the Gut Microbiota to Intestinal Fibrosis in Crohn's Disease
    Watanabe, Daisuke
    Kamada, Nobuhiko
    FRONTIERS IN MEDICINE, 2022, 9
  • [10] Hyperbaric Oxygen Therapy in the Management of Refractory Crohn's Disease
    Keihanian, Sara
    Glover, Sarah C.
    GASTROENTEROLOGY, 2015, 148 (04) : S863 - S864